VITRAKVI®
(larotrectinib) Capsules and Oral Solution
DESCRIPTION
Larotrectinib is a kinase inhibitor. VITRAKVI
(larotrectinib) capsules and oral solution are formulated using larotrectinib
sulfate. The molecular formula for larotrectinib sulfate is C21H24F2N6O6S
and the molecular weight is 526.51 g/mol for the sulfate salt and 428.44 g/mol for
the free base. The chemical name is (3S)-N-{5-[(2R)-2-(2,5-difluorophenyl)-1- pyrrolidinyl]pyrazolo[1,5-a]pyrimidin-3-yl}-3-hydroxy-1-pyrrolidinecarboxamide
sulfate. Larotrectinib sulfate has the following chemical structure:
Larotrectinib sulfate is an off-white to pinkish yellow
solid that is not hygroscopic. The aqueous solubility of larotrectinib at 37°C
is pH dependent (very soluble at pH 1.0 and freely soluble at pH 6.8, according
to USP descriptive terms of solubility).
VITRAKVI (larotrectinib) capsules and oral solution are
for oral use. Each capsule contains 25 mg or 100 mg larotrectinib (30.7 mg and
123 mg larotrectinib sulfate, respectively) in a hard gelatin capsule. The
capsule is composed of gelatin, titanium dioxide, and edible ink.
The oral solution contains 20 mg/mL larotrectinib (24.6
mg/mL larotrectinib sulfate) and the following inactive ingredients: purified
water, hydroxypropyl betadex, sucrose, glycerin, sorbitol, citric acid, sodium
phosphate, sodium citrate dihydrate, propylene glycol and flavoring. Preserved
with methylparaben and potassium sorbate.